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Abstract 
Background: Worldwide, non-small cell lung cancers have the highest incidence and mortality rates of all cancers. 
Gemcitabine (2’,2’-difluoro-2’-deoxycytidine or dFdC, C9H11F2N304) is widely used as the first-line chemo-reagent 
for lung cancer patients whose tumors have been diagnosed to be at an advanced stage and are therefore unresectable. 
Objective: The objective of this systematic study was to establish the correlation between the plasma concentration 
of gemcitabine and short-term clinical efficacy and adverse reactions in patients with advanced squamous cell 
carcinoma of the lung using liquid chromatography-mass spectrometry. 
Material and methods: In total, 53 patients were given the chemotherapy medications, gemcitabine and cisplatin, 
every 3 weeks. Plasma concentrations of gemcitabine were determined using liquid chromatography-mass 
spectrometry. A modified methodology of the liquid chromatography-mass spectrometry system was verified and 
performed to detect plasma concentrations of gemcitabine. The clinical endpoints – short-term clinical efficacy and 
adverse reactions – were evaluated after two cycles.  
Results: The plasma concentration range of gemcitabine in 53 patients was 1.58-28.70μg/ml (mean 
14.37±8.63μg/ml), with 28 patients in the >15μg/ml group (mean 21.76±3.45μg/ml), and 25 patients in the ≤15μg/ml 
group (mean 6.09±3.57μg/ml). The clinical benefit rate (CBR) of the >15μg/ml group was significantly higher than 
that of the 15μg/ml group (p<0.05). The incidences of leukopenia and neutropenia, thrombocytopenia and grade III-
IV gastrointestinal reactions in the >15μg/ml group were significantly higher than in the ≤15μg/ml group (p<0.05). 
There was no statistical difference between the two groups in terms of the incidences of reduced hemoglobin, liver 
and kidney function damage, allergic reaction and rash (p>0.05). The analysis of the plasma concentration of 
gemcitabine and the percentage of reduction in neutrophil count (NEUT) (r2 = 0.3212; p<0.05) and platelet (PLT) 
(r2 = 0.6439; p<0.05) showed a significant positive correlation.  
Conclusions: In patients with advanced non-small cell lung cancer, a high plasma concentration of gemcitabine can 
improve the short-term clinical efficacy of treatment, but increase the incidence of grade III-IV adverse reactions. 
[Ethiop. J. Health Dev. 2021; 35(1):72-82] 
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Introduction 
Over the past five decades, lung cancer has remained the 
most prevalent and lethal of all types of cancer (1). The 
latest data, from 2019, shows that China is significantly 
higher than the rest of the world in terms of the 
morbidity and mortality of lung cancer. The Chinese 
population accounts for 18.6% of the global population, 
while morbidity and mortality from lung cancer in China 
accounts for 37.0% and 39.2%, respectively, of all cases 
across the globe (1-4). The major therapies used for lung 
cancer depend on the subtype. For example, patients 
with non-small cell lung cancer (NSCLC) mainly rely 
on surgery combined with chemotherapy (5, 6). When 
lung cancer progresses to an advanced stage, only 
chemotherapy can delay its rapid development (7, 8). A 
very small proportion of NSCLC cases in specific 
mutated sites can benefit from targeted drugs; the rest of 
the large number of patients are treated with cytotoxic 
reagents only (8, 9). Gemcitabine, combined with 
platinum-based drugs, is the first-line chemotherapeutic 
regimen for NSCLC (10, 11). Research shows that the 
response rate of NSCLC patients treated with 
gemcitabine combined with cisplatin is 31-54%, and the 
average survival time is 8.4-15.4 months, with tolerable 
adverse reactions (12,13). 
 
Gemcitabine’s mechanism of action is different from 
other antinucleotide metabolizers, such as cisplatin and   
fluorouracil. Gemcitabine is a novel nucleoside 
derivative of cytosine, Activated by deoxycytosine 
kinase in the human body. The double fluorinated 
substitution of furanose stabilizes the electron density of 
furanose, leading to the accumulation of fluorinated 
cytidine. Fluorinated cytidine is then catched by guanine 
to form DNA double strands, escaping exonuclease 
detection, thereby starting apoptosis progress (14). 
Given gemcitabine’s broad variety of effects in a wide 
range of individuals, surveillance of blood concentration 
and monitoring of adverse events are required. (15,16). 
When gemcitabine came onto the market, At the early 
stage of gemcitabine marketing, there were reports on 
plasma drug concentration, but the number of research 
reports was few. According to the narrow safety margin 
of gemcitabine, related clinical studies show that there 
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are significant individual differences in terms of its 
clinical efficacy and adverse reactions among patients. 
When standard doses of gemcitabine are intravenously 
injected, the peak of plasma concentration reaches 
around 10～30μg/ml (17). This wide range of effective 
drug concentration easily leads to unmanageable life-
threatening side-effects. However, there is no integrated 
and standardized baseline, nor is there an effective 
technique for monitoring the dynamic plasma 
concentration of gemcitabine. Again, this is not clear. 
Perhaps: Thus, the monitoring of adverse events was 
based entirely on the self-reports of patients and 
observations of medical staff. But none of these options 
could achieve prediction of side-effects. Whether 
gemcitabine concentration can be used as a predictor of 
adverse reactions to guide individualized medication. 
There are several side-effects that may arise from this 
medication, including the suppression of bone marrow 
function; the loss of white blood cells, red blood cells 
and platelets; loss of appetite; and headaches. One 
particularly serious side-effect is thrombotic 
thrombocytopenic purpura. The use of a bone marrow 
stimulant while going through the drug administration 
and the use of antiemetic drugs can reduce the chance of 
associated side-effects. 
 
Since plasma concentration is commonly used as a 
reference basis in clinical practice, High Performance 
Liquid Chromatography (HPLC) is the prevalent 
method for detecting plasma gemcitabine (18). Chiral 
column chromatography is expensive and analytical use 
may be restricted by poor reproducibility. A major 
limitation is that it requires different stationary phases 
for each new class of optical isomer for better 
separation. Since the method for isolating plasma 
mixture relies on specific retention time, components 
with the same retention time would be automatically 
classified as one group. This would easily introduce 
false positive results if the components have similar 
polarities. In order to precisely separate the accurate 
gemcitabine active substrate, liquid chromatography-
mass spectrometry (LC-MS) was conducted to further 
separate mixtures and identify whether the component 
contains other impurities with the same retention time 
(19). The detection of serum gemcitabine using the LC-
MS method has been administered in Europe and the 
USA, although the HPLC technology remains the major 
monitoring method in China. The first observation point 
was the feasibility of the LC-MC for the determination 
of Plasma concentrations of gemcitabine in Chinese. 
The other observation point was the correlation between 
plasma concentration of gemcitabine and clinical 
efficacy and adverse events. Besides, due to the low 
selectivity of gemcitabine to tumor cells, some patients 
experienced adverse reactions at low concentrations of 
gemcitabine l. Once an adverse event happens, drug 
withdrawal only stops the exogenous increase of 
gemcitabine. Those adverse events also cause additional 
medical expenditure.  
 
Aiming at better sensitivity and a lower limit of 
detection, we managed to test whether the LC-MS 
method suited Chinese patients. Grade III-IV adverse 
events among patients treated with gemcitabine reached 
about 40% in our local center; the lower effective 
plasma level needed to be monitored, which might lead 
to a decline in the level of detection. In this study, we set 
up and modified the LC-MS technology, replacing 
traditional reversed-phase iron-pair HPLC to detect 
plasma gemcitabine in 53 lung cancer patients. The 
lowest threshold of detection reached 0.052ng/ml under 
the LC-MS system. Additionally, we integrated the 
distribution of the plasma level and its positive 
correlation with hematology adverse events.  
 
Materials and methods 
Analysis of the plasma concentrations of gemcitabine 
and other chemicals: Gemcitabine hydrochloride 
standard substances (purity: 99.8%, LOT 100622-
201202, molecular weight: 263.198g/mol) and cefaclor, 
internal standard (purity: 95.3%, LOT 130481-201205), 
were purchased from the National Institutes for Food 
and Drug Control. All chemicals were of standard 
analytical grade. Acetonitrile and formic acid were 
purchased from Merck KGaA (Darmstadt, Germany). 
With respect to the toxicity level, acetonitrile is highly 
discouraged for use as a solvent, With respect to its 
toxicity level, acetonitrile is highly discouraged for use 
as a solvent, but it was chosen on the basis that it has a 
lower viscosity than methanol, which forms highly, 
which forms highly viscous mixtures with water at 
certain concentrations. Also, acetonitrile has a higher 
elution strength than methanol. The water purification 
system used was provided by Millipore Inc. (Bedford, 
USA).  
 
The plasma concentrations of gemcitabine were 
determined by the LC-MS system. The working 
principle of the system involves the heat treatment of a 
sample mixture which separates into individual 
substances. Although heated gases are carried through a 
column with an inert gas (e.g. helium), in this study the 
high temperature heat treatment would reduce the 
efficacy of gemcitabine active compounds. Another 
reason of using the LC-MS method in this study on the 
basis of solvent selection with proper affinity.  
 
Three main classes of test procedures can be adopted for 
drug resistance during treatment, after a certain period 
of drug administration:  
1. Fresh tumor cell culture  
2. Cancer biomarker tests  
3. Positron emission tomography. 
 
LC equipment and conditions: The liquid 
chromatography phase of plasma gemcitabine was 
separated using Waters Acquity UPLC H-Class system 
(Waters, Milford, MA, USA). Agilent ZORBAX 
Eclipse Plus, C18 reversed-phase column (2.1×150mm 
1.8-micron) (Waters, Milford, MA, USA) was adopted 
and the column temperature was kept at 40℃. The 
mobile phase: water (containing 0.1% formic acid): 
acetonitrile (containing 0.1% formic acid) = 80:20. 
Elution rate was applied at 0.4ml/min.  
 
Mass spectrometry equipment and conditions: A Xevo 
triple quadrupole (TQD) mass spectrometry with an 
electrospray ionization (ESI) (SCIEX, Framingham, 
MA, USA) source operating in the positive mode was 
used as a quantitative detector. For quantification, 
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multiple reaction monitoring (MRM) chromatograms 
were acquired. Optimized MS parameters included: 
capillary voltage 1,000V, source temperature 550℃. A 
retaining cone was used as 1,000 l/hr nitrogen gas and 
collision gas was conducted by 50 l/hr.  
 
Standard solution and quality control (QC): The total 
11.40mg standard gemcitabine was weighed twice and   
dissolved in 10ml methanol to get 1mg/ml stocking 
solution. With cefaclor as the internal standard, the 
internal standard method of quantitative. 10.5mg   
standard cefaclor was weighed twice and dissolved into 
a volumetric flask with 50ml solution of 10mmol/l 
ammonium acetate to get 0.20mg/ml cefaclor stocking 
solution. The working solution was diluted by the 
water–acetonitrile (4:1, V/V) to 8μg/ml before use. Each 
standard concentration (50μl) was added to 50μl blank 
plasma, followed by mixing with 100μl  8μg/ml 
cefaclor, Q500ng/ml solutions. The low (10ng/ml), 
medium (50ng/ml) and high (400ng/ml) QC solutions 
were prepared in a similar manner. The cefaclor and QC 
solutions were stored at 4℃.  
 
Sample preparation: Plasma samples were gradually 
thawed at room temperature, and then 50μl of each 
sample was mixed with 100μl of internal standard 
working solution and 50μl of water–acetonitrile (4:1, 
V/V) mixture. The plasma sample mixture was then 
vortexed for 5 minutes at 1,250 rpm, followed by being 
centrifuged at 15,000rpm for 5 minutes. The supernatant 
was carefully collected and filtered through a 0.22μm 
organic membrane. The final extraction was transferred 
to auto sampler vials with inserts for loading analysis. 
All samples were stored at −80℃ until further use. 
 
Method validation: We followed the guidelines of the 
US FDA Guidance for Industry Bioanalytical Method 
Validation, as well as guidelines produced by the 
European Medicines Agency and Chinese 
Pharmacopoeia (2015). 
 
The validation of the method was carried out for 
sensitivity, selectivity, standard cure and low of limit, 
precision and recovery rate, matrix effect, residue effect, 
continuous calibration (CC) standards and QC samples.  
 
Specificity: 50μl each of standard gemcitabine solution 
series and blank plasma sample were mixed with an 
additional 50μL of (water:acetonitrile = 4:1), vortexed 
for 30 seconds, and centrifuged for 5 minutes at 1,5000 
rpm. The supernatant was passed through a 0.22μm 
organic filter, and 5μl was taken for simultaneous 
injection, and the chromatogram results were recorded. 
 
Investigation focused on whether the samples, internal 
standard, and plasma substances could be completely 
separated without interference of gemcitabine. 
 
Standard curve and low of limit: The chromatogram 
results of each standard solution were recorded. The 
peak area ratios of gemcitabine and the internal control 
(Cefaclor) were plotted as ordinate (y-axis), and the 
concentration of gemcitabine was plotted as abscissa (x-
axis). Next, the linear regression between these two 
factors was analyzed, thereby obtaining standard curve 
and low of limit. 
 
Recovery and precision: Three QC solutions with 
concentrations of 10, 50, 400ng/ml-1 were prepared 
using the process indicated above. Each concentration 
had five repetitions, and each sample was determined 
continuously in three days in order to calculate the inter- 
and intra-day precision and recovery. 
 
Matrix effects: Six plasma samples of the same 
concentration were prepared, three with matrix and three 
without matrix. The peak ratio of matrix with matrix-
free was calculated. The ideal ratio should be within the 
85%-115% range. 
 
Residual effects: High QC solutions and five plasma 
samples with different batches were alternatively 
injected to determine whether any residue existed after 
injecting the high QC solution.  
 
Stability: Low, medium and high QC working solutions 
were placed at room temperature and 4℃, respectively. 
Re-determination of concentration for each sample was 
conducted at 0, 4, 8, 12 and 24 hours. The change of 
concentration in each solution that were stored for 90 
days at –20oC and 180 days at –80oC was conducted as 
freeze-thaw stability. 
  
Patient enrolment: Eligibility criteria included: 
1. Patients with cytological or pathological diagnosed 
advanced lung squamous cell carcinoma (III B/IV) 
2. Medical records ranging from January 2017 to June 
2018 in the people’s hospital of Guangxi Zhuang 
autonomous region 
3. 18-75 years of age 
4. Eastern Cooperative Oncology Group(ECOG) 
score ≤2 
5. Expected survival time >3 months 
6. Measurable lesion ≥1 and no brain metastases 
7. No gastrointestinal diseases and symptoms before 
chemotherapy 
8. No cardiac, hematological, liver or renal function 
anomalies 
9. No disequilibrium of basic metabolism 
10. No radiotherapy or receiving radiotherapy after 6 
weeks. 
 
Exclusion criteria included: 
1. Chemotherapeutic cycle <2 
2. Preventive conduction of granulocyte colony 
stimulating factor (G-CSF) or pharmacologically 
similar drugs before chemotherapy 
3. Concurrent combination of radiotherapy. 
 
All of the enrolled patients signed informed consent 
forms, and the study was approved by the ethics 
committee of the people’s hospital of Guangxi Zhuang 
autonomous region. 
 
Therapeutic protocol: All patients received intravenous 
injections of 1,000mg/m2 gemcitabine (Gemzar®, 
LOT676406, Eli Lilly and Company, Indianapolis, 
USA) and 75mg/m2 cisplatin (LOT130701, Hansoh 
Pharma, Jiangsu Province, China). Freeze-dried 
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gemcitabine was diluted with 100ml 0.9% NaCl solution 
before use and then slowly dripped within 30 minutes on 
day 1 and day 8 of the therapy cycle, cisplatin was 
diluted in 500ml 0.9% NaCl solution before use and then 
slowly dripped within 60 minutes on day 1 of the therapy 
cycle. 
 
Sample collection: For each patient, a total of 2-3ml of 
venous blood was collected in EDTA-anticoagulated 
tubes within 5 minutes of finishing the infusion of 
gemcitabine. All samples were labeled and immediately 
placed in an ice water bath and transferred to the 
laboratory. Plasma was then separated by centrifuge 
(Thermo X3R) at 4℃ at 3,000 rpm for 30 minutes. Each 
plasma sample was stored at –20℃ before 
determination. The determination was conducted within 
one week. 
 
Observation target and evaluation: Baseline evaluation 
was integrated through manifestations and objective 
examination. Patients’ manifestations contained the 
aspects of gender, age, weight, pathological type, ECOG 
PS, chest X-ray, CT and other imaging data. Laboratory 
examination included blood routine examination, liver 
and kidney functions, and cardio functions. After two 
cycles of chemotherapy, the short-term clinical efficacy 
of the patients was evaluated by measuring the tumor 
focus based on imaging data. Adverse side-effects, 
including gastrointestinal reaction, myelosuppression, 
liver and kidney injury, allergic reaction and skin rash, 
were recorded and evaluated at the end of each cycle. 
The percentage reduction in neutrophil count and 
platelet (PLT) was calculated as follows:  
 
NEUT and PLT (%) = ×100%. 
 
The short-term clinical efficacy was measured by 
Objective Response Rate (ORR) and clinical benefit rate 
(CBR). It was classified as complete response (CR), 
partial response (PR), stable disease (SD) and 
progression of diseases (PD), based on the response 
evaluation criteria for solid tumor therapy (RECIST) 
(8).  
ORR= ×100%, CBR =
×100%. 
Adverse reactions were determined as the most severe 
reaction after each cycle of chemotherapy and recorded 
in the analysis as statistical data. The classification was 
carried out according to the classification standards for 
acute and subacute toxic and side-effects of anticancer 
drugs. 
 
Statistical analysis: Data are presented as mean ± SD 
(median); all data were analyzed for descriptive 
statistics using SPSS version 22 (IBM, USA); the 
plasma concentrations were compared with a paired 
Student’s t-test; the adverse reaction and short-term 
clinical efficacy rates were compared with a chi-square 
test, the level of significance of which was set at p<0.05. 
 
Results: Method validation 
Specificity: The LC-MS system was used to test the 
retention time of gemcitabine and the internal control, 
cefaclor (cefaclor is a second generation cephalosporin 
antibiotic, extensively used to treat bacterial infections 
of respiratory tract, skin, ears, throat, tonsils and urinary 
tract. Molecular formula: C15H14ClN304S; molecular 
weight: 367.8g/mol). cefaclor was plotted as ordinate 
(y-axis), and the concentration of gemcitabine was 
plotted as abscissa (x-axis). Linear regression analysis 
was carried out for further interpretation. Endogenous 
substrate of plasma did not interfere with either 
gemcitabine or cefaclor, thereby proving the good 
specificity of the LC-MS method. 
 
Standard curve and low of limit: The standard curve for 
gemcitabine in plasma was linear over the range 5ng/ml 
to 500ng/ml; the standard curve’s regression was 
C=1272.93A+11213.5, r = 0.999. The lower limit of 
quantitation for gemcitabine and QC cefaclor in plasma 
was 0.052ng/ml. 
 
Recovery and precision: The RSD (recovery and 
relative standard deviation) value of recovery of 
precision among low, medium and high QC solutions 
ranged from 89.41% to 101.42%. The intra-day RSD 
and inter-day RSD of these three QC solutions were 
4.55%, 3.09% and 2.81% vs 6.92%, 5.22% and 3.63% 
(see Table 1). 
 
Table 1: Precision and recovery of gemcitabine in plasma 
Concentration Intra-day RSD (%) Inter-day RSD (%) absolute recovery (%) 
10 4.55 6.92 89.41 
50 3.09 5.22 98.38 
400 2.81 3.63 101.42 
 
Matrix and residue effects: The matrix effects results of 
low, medium and high QC solutions fluctuated around 
92-108%, and the high QC solution had no residue 
according to its chromatogram. These results indicated 
that the matrix could not disturb the results and the 
method would not cause residue effect. 
Stability: Three QC solutions obtained good short-term 
routine storage and long-term cryopreservation. The 
RSD value of each determination of concentration was 
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10 4.26 4.78 11.67 14.33 
50 4.17 3.96 10.46 16.52 
400 2.36 2.85 7.98 13.87 
 
Results: Demographic information and clinical 
baseline 
Fifty-three patients were enrolled in this study: 33 males 
and 20 females. Their ages ranged from 23 to 75 years, 
averaging 54.1±10.96 years old. For all the participants, 
the median plasma concentration of gemcitabine was 
15μg/ml, which further was treated as a cut-off value to 
classify high (>15μg/ml) and low (≤15μg/ml) 
concentration groups. Details of the demographic 
information of participants are in Table 3. There was no 
statistical difference between the two groups in terms of 
age, gender, body mass index (BMI), pathological type, 
disease stage and ECOG score (p>0.05). 
 
Table 3: Comparison of demographic information of the two groups 
 >15μg/ml group ≤15μg/ml group X2 P 
Total case 28 25   
Average age 55.7±9.0 years 53.22±11.2 years 0.428 0.527 
Gender (male:female) 17:11 16:9 0.391 0.412 
BMI (kg/m2) 21.83±5.83 23.16±4.26 0.097 0.785 
Pathological type 




16/8/1 (64.00%/32.00%/4.00%) 0.476 0.469 
Tumor stage (III B/IV) 10/18 (35.71%/64.29%) 8/17 (32.00%/68.00%) 1.247 0.264 
ECOG PS (0/1/2) 
18/8/2 
(64.29%/28.57%/7.14%) 
17/8/0 (68.00%/32.00%/0.00%) 1.683 0.192 
 
Results: Distribution of plasma gemcitabine 
The distribution of plasma gemcitabine concentration 
among 53 patients complied with non-normal 
distribution. The plasma gemcitabine concentration 
ranged from 1.58μg/ml to 28.70μg/ml, with an average 
concentration of 14.37±8.63μg/ml, as shown in Table 4 
and Figure 1.  
 

















1 1.58 15 3.82 29 18.78 43 22.07 
2 1.96 16 7.93 30 24.27 44 19.16 
3 2.06 17 7.52 31 16.85 45 28.7 
4 2.18 18 7.91 32 20.76 46 25.48 
5 2.54 19 8.04 33 24.93 47 19.39 
6 3.17 20 8.21 34 23.84 48 27.18 
7 3.68 21 9.76 35 22.17 49 19.05 
8 4.08 22 11.06 36 25.78 50 23.84 
9 4.96 23 13.78 37 21.46 51 17.32 
10 5.78 24 14.89 38 27.36 52 16.81 
11 6.13 25 5.81 39 19.26 53 21.83 
12 6.82 26 15.76 40 24.14   
13 3.93 27 19.84 41 20.36   
14 4.71 28 19.84 42 23.14   
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Figure 1: Distribution of plasma concentration of gemcitabine among participants 
 
Results: Relationship between plasma gemcitabine 
and short-term clinical efficacy 
The clinical efficacy was evaluated as per the RECIST 
guideline. The disease response rates are listed in Table 
5. The high plasma gemcitabine concentration group 
(>15μg/ml) showed a better CBR score of 85.71% 
compared with 76.00% for the low plasma gemcitabine 
concentration group (≤15μg/ml) (p = 0.036), which 
implies that patients with a plasma gemcitabine 
concentration over 15μg/ml might obtain promising 
clinical benefits. There was a similar tendency between 
two groups in relation to the ORR score – the high 
plasma gemcitabine concentration group (>15μg/ml) 
scored a higher ORR (35.71%), whereas the lower score 
of 28.00% was illustrated in their counterparts, with no 
statistical significance. 
 
Table 5: The relationship between the concentration of gemcitabine and short-term efficacy 
Concentration CR PR SD PD ORR CBR 
>15μg/ml 3 (10.71%) 7 (25.00%) 14 (50.00%) 4 (14.29%) 35.71% 85.71% 
≤15μg/ml 2 (8.00%) 5 (20.00%) 12 (48.00%) 6 (24.00%) 28.00% 76.00% 
x2 - - - - 2.533 4.248 
P - - - - 0.053 0.036 
Note: ORR: Objective Response Rate; CBR: clinical benefit rate; CR: complete response; PR: partial response; SD: 
stable disease; PD: progression of diseases. 
 
Results: High plasma gemcitabine predicted 
particular adverse events 
Although high plasma gemcitabine relates to better 
clinical efficacy, it was unknown if it was related to any 
consequent adverse events. Therefore, all of the enrolled 
subjects were under medical surveillance any adverse 
events occurred during the first two cycles. 
Gastrointestinal reactions remained the most prevalent 
adverse events in both groups, with an incidence of 
82.14% in the high plasma gemcitabine group and 72% 
in the low plasma gemcitabine group, regardless of the 
severity grade. Patients with low plasma gemcitabine 
had a slightly higher proportion of the occurrence of 
mild side-effects (level I-II) in terms of gastrointestinal 
reactions, liver injury and renal function, though none of 
them showed statistical significance (p>0.05, see Table 
6). 
 
Table 6. The relationship between concentration of gemcitabine and adverse reactions 





n % N % 
Gastrointestin
al reaction 




≤15μg/ml 25 16 64.00 2 8.00 
Hepatic injury 












≤15μg/ml 25 3 12.00 0 0 
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For common chemotherapeutic conditions such as skin 
rash, influenza-like symptoms, anaphylaxis and 
alopecia, there was no obvious difference between the 
two groups (see Table 6). In terms of higher grade side-
effects (level III-IV), these were found in around one 
fifth of patients in the high plasma gemcitabine group 
and in 8% of patients in the low plasma gemcitabine 
group (see Table 7). The statistical difference between 
the two groups in terms of the incidence of level III-IV 
gastrointestinal reactions was significant (p<0.05)  
 
Table 7. The relationship between concentration of gemcitabine and other major adverse reactions 
Adverse 
reactions 
N Skin rash Influenza-like 
symptoms 
Anaphylaxis Alopecia  Others  
  n % n % n % n % n % 
 >15μg/ml 28 3 10.71
% 





≤15μg/ml 25 2 
 





x2 - 0.18  0.274  0.76
4 
 0.417  0.532  
P - 0.66
7 
 0.752  0.36
7 
 0.623  0.455  
 
 In addition, we found that all participants suffered 
different levels of chemotherapy-related 
myelosuppression, which leads to irreversible and lethal 
events. The high plasma gemcitabine group had a higher 
incidence of induced leucopenia, granulocytopenia and 
thrombocytopenia compared to the low plasma 
gemcitabine group at all grades of severity. Chi-square 
analysis demonstrated that the difference of incidence 
between the two groups was statistically significant 
(p<0.05).  
 
Since the obvious higher possibility of chemotherapy-
related myelosuppression occurred among patients with 
high plasma gemcitabine, we assumed that the severity 
of chemotherapy-related myelosuppression was induced 
by an increase in plasma gemcitabine. According to the 
evaluation assessment, the severity of myelosuppression 
was positively related to the reduction in their plasma 
level. Spearmen correlation analysis was conducted to 
determine the correlation between plasma gemcitabine 
and the reduction of plasma level of NEUT and PLT, 
respectively. The increased reduction of NEUT and PLT 
was positively correlated with higher plasma 
gemcitabine. Figure 2A and 2B show the correlation 
between NEUT, PLT and the plasma concentration of 
gemcitabine individually. The specific coefficient r2 for 
NEUT reduction was 0.827 (p<0.05), and 0.578 
(p<0.05) for PLT reduction (see Table 8), which 
instructed the higher plasma gemcitabine reflected the 
higher the incidence of myelosuppression. Based on 
these data, the surveillance of plasma gemcitabine could 
be used as a predictor of adverse reactions to guide 
individualized medication.  
 
Table 8: The relationship between concentration of gemcitabine and myelosuppression 
 
Different anticancer drugs are used to treat different 
types of tumors, with different drug categories affecting 
abnormal cells in many ways. They have different 
origins and target component cells and have side-effects 
on the human body. The treatment regime of anticancer  
 
drugs are such that drugs are given for a set time 
duration at repeated intervals. Chemotherapy drugs may 
be given according to different schedules. In Table 9 we 
summarize other anticancer drugs and corresponding 






Adverse Reactions N 




n % n % n %   n % n % n %   
Leukopenia 
>15 µg/ml 28 7 25.070 5 17.86 12 42.86 
5.13 0.029 
4 14.29 3 10.71 7 25.00 
4.42 0.031 
≤15 µg/ml 25 5 20.050 3 12.00 8 32.00 2 8.00 2 8.00 4 16.00 
Granulocytopenia 
>15 µg/ml 28 7 25.070 3 10.71 10 35.71 
4.33 0.046 
3 10.71 3 10.71 6 21.43 
4.87 0.049 
≤15 µg/ml 25 5 20.050 2 8.00 7 28.00 2 8.00 2 8.00 4 16.00 
Decreased 
Haemoglobin 
>15 µg/ml 28 4 14.249 2 7.12 6 21.43 
0.25 0.628 
3 10.71 1 3.57 4 14.29 
0.27 0.794 
≤15 µg/ml 25 3 12.030 2 8.00 5 20.00 2 8.00 1 4.00 3 12.00 
Thrombocytopenia 
>15 µg/ml 28 6 21.463 3 10.71 9 32.14 
9.11 0.004 
3 10.71 3 10.71 6 21.43 
4.22 0.022 
≤15 µg/ml 25 3 12.030 2 8.00 5 20.00 2 8.00 1 4.00 3 12.00 
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Table 9: List of generic oncology products, originator products, and the corresponding tumor cell 
lines used 
 
Generic oncology  Originator   Tumor cell line   Origin products    
    used 
 
Paclitaxel     Taxol      MCF-7  Breast carcinoma 
NCI-H2126         Non-small cell lung carcinoma 
Docetaxel    Taxotere      MCF-7  Breast carcinoma 
SKOV-3  Ovarian carcinoma 
PC-3   Prostate carcinoma 
NCI-H2126         Non-small cell lung carcinoma 
Oxaliplatin    Eloxatin      HT-29  Colorectal carcinoma 
Bicalutamide    Casodex      PC-3   Prostate carcinoma 
Anastrozole    Arimidex    MCF-7  Breast carcinoma 
 
 
Figure 2: The correlation between NEUT, PLT and plasma concentration of gemcitabine 
 
Discussion 
We chose gemcitabine over other drugs, such as 
cisplatin and fluorouracil, because related clinical 
studies indicate its wide range of acceptability among 
patients, given its easy penetration into cell DNA 
compared to other drugs. The optimum concentration 
for application is still under study. First, we considered 
two problematic issues: the condition of traditional RP-
liquid chromatographic methodology with an extremely 
short retention time for weak basic compounds; and the 
complicated mixture of human plasma, which easily 
interferes with the accuracy of separation (20). Due to 
the basic deoxycytidine structure of gemcitabine, its 
extremely strong polarity makes it difficult to retain in a 
normal chromatographic column (20,21). Therefore, in 
this study, the column that applied in liquid 
chromatography was replaced by ZORBAX Eclipse 
PlusC18, which was a modified porous RP-C18 silica 
gel with ultra-high purity level through chemical 
bonding dimethyl-n-octadecylsilane to ZORBAX Rx-
SIL silica gels (Class B). Silica column normal was 
conducted for separating acidic and neutral sample, 
since the basic compounds would form tight bonds with 
padding. However, the ZORBAX modified silica 
column can reduce and eliminate the strong adhesion of 
basic and highly polar compounds through covalent 
binding with octadecylsilane (22). Therefore, this 
modified chromatographic column was widely applied 
to separate alkaline with increasing accuracy. 
 
As for reducing the interference of the plasma mixture, 
the protein precipitation was a key step for filtrating the 
major impurity, thereby improving the chromatographic 
accuracy (23). Plasma contains various proteins with 
polarity affecting pH value; their amino acid residue 
normally carries different charges which could disturb 
the chemical’s retention. Besides, the large molecular 
weight of protein blocks the filtration of the impurity. In 
the preliminary experiment, three combinations of 
organic reagents were used for precipitating plasma 
protein: 30% trichloroacetic acid and water solution, 
methanol and acetonitrile (1:9 V: V) solution, and water 
and acetonitrile (4:1 V: V) solution. The results showed 
the sample peak and its tailing factor were dramatically 
improved, as well as increasing the signal response of 
gemcitabine under pre-treatment with the water and 
acetonitrile (4:1 V:V) solution compared to the other 
two precipitated solutions. Although these three 
combinations were all certified protein precipitation 
reagents, in our system, the water and acetonitrile 
mixture achieved the most optimal exclusion of plasma 
protein. 
 
We also modified the condition of the mobile phase with 
a slightly decreasing pH value to obtain a better signal 
response value of both gemcitabine and cefaclor. Four 
mixtures containing different weak acid concentrations 
were applied for candidate elution: A. 0.52% sodium 
dihydrogen phosphate solution (pH 2.66) and 
acetonitrile (85:15, containing 0.202% sodium heptane 
sulfonate); B. 0.01% acetic acid water and acetonitrile 
(80:20); C. acetonitrile: 0.1% trifluoroacetic acid (3:97); 
and D. 40 mol/l ammonium acetate buffer and 
acetonitrile (97.5:2.5). Elutions A and B decreased the 
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tailing effects and increased the signal response value of 
both gemcitabine and cefaclor, which reflected in a 
better and specific peak shape in their chromatogram. 
Given the inherent properties of gemcitabine, an 
additional weak acid component could eliminate the 
uneven tight bond between it and column padding, 
resulting in a constant stable eluant velocity. However, 
the pH value also restricts at small scale, since the 
dramatic change in ion strength, compound dissociation 
and charge equilibrium would neutralize gemcitabine 
and interrupt the eluent order.  
 
Therefore, the administration of methodology in our 
LC-MS system was optimal for testing the plasma 
concentration of gemcitabine (24). The plasma 
concentration of gemcitabine in 53 patients had a 
positive correlation with short clinical efficacy as well 
as severe myelosuppression. Except for 
myelosuppression, high and low plasma concentrations 
of gemcitabine had no obvious difference in organ 
function, such as liver, kidney and heart, nor in common 
indices, such as gastrointestinal reaction, skin-related 
symptoms and anaphylaxis. Our results showed a high 
incidence of gemcitabine-related myelosuppression 
among NSCLC patients; Tian et al. reported similar 
results of major side-effects (25). A similar research 
study of 82 patients also indicated that nearly 25% of 
pancreatic cancer patients suffered level III-IV 
myelosuppression after administering gemcitabine (26). 
A higher incidence of gemcitabine-related 
myelosuppression was also observed among solid tumor 
patients with nicotine accumulation (27). 
 
To avoid non-tumor-related deaths, dose reduction or 
drug withdrawal was normally applied when severe 
side-effects occurred. This intervention led to a drop in 
the plasma concentration of gemcitabine, thereby 
attenuating clinical short-term efficacy. Though the 
range of effective plasma concentrations of gemcitabine 
is unclear, a low concentration of gemcitabine might 
accelerate the metabolism of tumor cells, which 
furthered activate the proliferative signal of tumors 
(7,28). If patients could tolerate side-effects, increasing 
the dose to the peak level relative to the high level of 
plasma concentration might improve their short-term 
clinical efficacy. The good tolerance in the first two 
cycles might aggrandize patients’ compliance. Also, a 
constant high level of gemcitabine might cause 
resistance towards normal cells, due to the 
hyposensitization of continuous strong activation from 
gemcitabine (29).  
 
The side-effects of chemo-reagents should be prevented 
when they can be predicted. In order to decrease 
gastrointestinal reaction, therapy involved the high 
possibility of causing nausea or vomiting was suggested 
with addition of antiemetic drugs at the initiation of 
chemo-cycle especially combine with cisplatin reagent 
(30). According to our results, we assumed the 
surveillance of plasma concentration of gemcitabine and 
the premonitory symptom of myelosuppression called 
up exogenous supplement of colony-stimulating factor, 
since the timing administration of bone marrow 
stimulant might compensate for the slight 
myelosuppression (31,32). 
Conclusions 
The modified LC-MS methodology was suitable for 
detecting the plasma concentration of gemcitabine. The 
plasma concentration of gemcitabine was positively 
associated with adverse reactions and short-term 
curative effects in patients with advanced NSCLC. High 
plasma concentrations can improve the short-term 
clinical efficacy of gemcitabine treatment, but increase 
the incidence of grade III-IV adverse myelosuppression-
related events. 
 
The research team for this study is planning to prolong 
the clinical observation and incorporate the survival 
rate, so that long-term efficacy can be evaluated. As 
metabolized gemcitabine suppresses tumor growth, if 
the metabolized type could be tested in parallel with 
prototype gemcitabine, the relationship between 
metabolism and side-effects would be worthy of further 
investigation. 
 
Limitations of the study 
The study was limited in terms of the scale of 
observation, namely the small number of patients 
observed in a single regional medical center. Extended 
recruitment with specific age tiers and tumor subtypes 
would have resulted in more evidence to establish the 
population pharmacodynamics of gemcitabine.  
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